bvand086/sciwritingdataset · Datasets at Hugging Face

text stringlengths 0 512
tion
This information included participant age, gender,
and primary and ancillary dystonic diagnoses
RESULTS
Participant demographics
The survey included a total of 158 participants comprised
of responses from 133 cisgender female participants and 25
cisgender male participants with a mean age of 64.8 years
old and participant age ranging from 22 years old to 95
years old (Figure 1)
Adductor spasmodic dysphonia was
the most common condition with 65 participants claiming
this diagnosis (Figure 1)
Mixed spasmodic dysphonia was
found to be the second most common with 37 responses
claiming this diagnosis, and abductor spasmodic dysphonia
closely followed at 30 participant responses (Figure 1)
Muscle tension dysphonia, vocal tremor, and vocal
FIGURE 1
Demographic data of participants capturing gender,
age, dysphonia, and dystonia outside the vocal cords
Journal of Voice, Vol
xx, No
xx, xxxx 2
Downloaded for Anonymous User (n/a) at McMaster University from ClinicalKey.com by Elsevier on September 08,
2023
For personal use only
No other uses without permission
Copyright ©2023
Elsevier Inc
All rights reserved
dystonia otherwise not specified were less common diag-
noses for this survey population (Figure 1)
A majority of
the respondents were not diagnosed with dystonia or
tremor elsewhere in their body, though 51 of the partici -
pants (32.3%) reported experiencing dystonia or tremor
beyond their vocal symptoms (Figure 1)
Participants using cannabinoid products to treat
vocal dystonia
Of the 85 (53.8%) participants who stated they had tried
using cannabinoid products at least once in the past to treat
their vocal condition (Figure 2A), 45 participants (52.9%)
stated they currently use cannabinoid products as treat -
ment (Figure 2A)
Among these participants, 24 partici -
pants (53.3%) used cannabinoid products daily (Figure 2B)
Eight participants used cannabinoid products once a week,
six participants used cannabinoid products multiple times a
week, and seven participants used cannabinoid products
more sparingly at once or twice a month (Figure 2B)
The
majority of participants reported using cannabinoid pro-
ducts to treat their symptoms for at least 1 year (58.8%)
with 28 of these participants (32.9%) reporting use for
approximately 1–2 years and 22 of these participants
(25.9%) reporting using for at least 3 years (Figure 2C)
Seventeen respondents reported using cannabinoid pro-
ducts for less than a month and 12 respondents reported
several months of use (Figure 2C)
Respondents were most likely to use cannabinoid pro-
ducts containing CBD alone (32 of 85 participants) or CBD
in combination with THC (39 of 85 participants) and were
less likely to use THC products alone (12 of 85 participants)
(Figure 3)
Among participants who actively used cannabi -
noids to treat their vocal condition, the most frequently used formulation of cannabinoid products was edible products,
with 29 respondents (64.4%) stating they used this pre-
paration (Figure 3)
Twelve participants who selected
“other” specified that they used a tincture preparation of
cannabinoids and one participant specified tablets, both of
which are oral formularies that can also be classified as an
edible cannabinoid product (Figure 3)
The second most
common mode of using cannabinoid products was via
smoke inhalation, with 16 participants (35.6%) using this
method (Figure 3)
Vaping was another common method of
using cannabinoid products with 10 participants (22.2%)
stating they used this formulation (Figure 3)
Topical can-
nabinoid products were the least commonly used product
with eight participants (17.8%) stating they used this pre-
paration; one participant who selected “other” specified that
they used CBD patches, which can be reclassified as a to-
pical preparation of cannabinoids (Figure 3)
Participants who did not use cannabinoid products
to treat vocal dystonia
Of the 158 respondents in total, 73 (46.2%) had never tried
using cannabinoid products to treat laryngeal dystonia/
vocal tremor/MTD (Figure 2)
Additionally, 40 re-
spondents stated they had tried cannabinoid products to
treat their condition but had since discontinued cannabi -
noid use (Figure 2)
The most commonly cited reason for
discontinuing cannabinoid use among respondents was the
ineffectiveness of these products in treating their under -
lying vocal condition, with 31 participants (77.5%) selecting

tion

This information included participant age, gender,

and primary and ancillary dystonic diagnoses

RESULTS

Participant demographics

The survey included a total of 158 participants comprised

of responses from 133 cisgender female participants and 25

cisgender male participants with a mean age of 64.8 years

old and participant age ranging from 22 years old to 95

years old (Figure 1)

Adductor spasmodic dysphonia was

the most common condition with 65 participants claiming

this diagnosis (Figure 1)

Mixed spasmodic dysphonia was

found to be the second most common with 37 responses

claiming this diagnosis, and abductor spasmodic dysphonia

closely followed at 30 participant responses (Figure 1)

Muscle tension dysphonia, vocal tremor, and vocal

FIGURE 1

Demographic data of participants capturing gender,

age, dysphonia, and dystonia outside the vocal cords

Journal of Voice, Vol

xx, No

xx, xxxx 2

Downloaded for Anonymous User (n/a) at McMaster University from ClinicalKey.com by Elsevier on September 08,

2023

For personal use only

No other uses without permission

Elsevier Inc

dystonia otherwise not specified were less common diag-

noses for this survey population (Figure 1)

A majority of

the respondents were not diagnosed with dystonia or

tremor elsewhere in their body, though 51 of the partici -

pants (32.3%) reported experiencing dystonia or tremor

beyond their vocal symptoms (Figure 1)

Participants using cannabinoid products to treat

vocal dystonia

Of the 85 (53.8%) participants who stated they had tried

using cannabinoid products at least once in the past to treat

their vocal condition (Figure 2A), 45 participants (52.9%)

stated they currently use cannabinoid products as treat -

ment (Figure 2A)

Among these participants, 24 partici -

pants (53.3%) used cannabinoid products daily (Figure 2B)

Eight participants used cannabinoid products once a week,

six participants used cannabinoid products multiple times a

week, and seven participants used cannabinoid products

more sparingly at once or twice a month (Figure 2B)

The

majority of participants reported using cannabinoid pro-

ducts to treat their symptoms for at least 1 year (58.8%)

with 28 of these participants (32.9%) reporting use for

approximately 1–2 years and 22 of these participants

(25.9%) reporting using for at least 3 years (Figure 2C)

Seventeen respondents reported using cannabinoid pro-

ducts for less than a month and 12 respondents reported

several months of use (Figure 2C)

Respondents were most likely to use cannabinoid pro-

ducts containing CBD alone (32 of 85 participants) or CBD

in combination with THC (39 of 85 participants) and were

less likely to use THC products alone (12 of 85 participants)

(Figure 3)

Among participants who actively used cannabi -

noids to treat their vocal condition, the most frequently used formulation of cannabinoid products was edible products,

with 29 respondents (64.4%) stating they used this pre-

paration (Figure 3)

Twelve participants who selected

“other” specified that they used a tincture preparation of

cannabinoids and one participant specified tablets, both of

which are oral formularies that can also be classified as an

edible cannabinoid product (Figure 3)

The second most

common mode of using cannabinoid products was via

smoke inhalation, with 16 participants (35.6%) using this

method (Figure 3)

Vaping was another common method of

using cannabinoid products with 10 participants (22.2%)

stating they used this formulation (Figure 3)

Topical can-

nabinoid products were the least commonly used product

with eight participants (17.8%) stating they used this pre-

paration; one participant who selected “other” specified that

they used CBD patches, which can be reclassified as a to-

pical preparation of cannabinoids (Figure 3)

Participants who did not use cannabinoid products

to treat vocal dystonia

Of the 158 respondents in total, 73 (46.2%) had never tried

using cannabinoid products to treat laryngeal dystonia/

vocal tremor/MTD (Figure 2)

Additionally, 40 re-

spondents stated they had tried cannabinoid products to

treat their condition but had since discontinued cannabi -

noid use (Figure 2)

The most commonly cited reason for

discontinuing cannabinoid use among respondents was the

ineffectiveness of these products in treating their under -

lying vocal condition, with 31 participants (77.5%) selecting